CompletedNCT06167577
Gene expression and antipsychotic response in bipolarity
About this title
Dysbindin-antipsychotics Psychophamarcogenetics: a Mouse-human Translational Study Towards Personalized Healthcare in Bipolar Disorders
Read the official source — NCT06167577Observational studyAges 18–65Italy
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- MilanSee all locations and recruitment
Study information
Study start dateStarted: November 8, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 150
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- DIAGNOSTIC_TEST
- Study phase
- Not clearly listed
- Locations
- Italy
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06167577
- Official title
Show the full official title
Dysbindin-antipsychotics Psychophamarcogenetics: a Mouse-human Translational Study Towards Personalized Healthcare in Bipolar Disorders GR-2016-02362413
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Milan
Questions about this study
Who is behind this study?
The study sponsor is Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
